Arterial Subtraction Images of Gadoxetate-Enhanced MRI Improve Diagnosis of Early-Stage Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is the most common primary hepatic malignancy and the third most frequent cause of cancer-related deaths.[1,2] Although the prognosis of patients with advanced HCC remains poor, patients with early-stage HCC are eligible for curative treatments such as surgical resection, local ablation, and liver transplantation.[3,4] Therefore, accurate imaging diagnosis of early-stage HCC is important.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Source Type: research

Related Links:

Hepatocellular carcinoma (HCC) is the second most common cause of cancer death worldwide, with a majority of HCC patients not suitable for curative therapies. Approximately 70% of initially diagnosed patients cannot undergo surgical resection or transplantation candidates due to locally advanced disease, poor liver function/underlying cirrhosis, or additional comorbidities. Local therapeutic options for patients with unresectable HCC, not suitable for thermal ablation, include transarterial embolization (bland, chemoembolization, radioembolization) and/or external beam radiation therapy (EBRT). Regarding EBRT specifically,...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conclusion: Our data indicate that the risk of microvascular invasion is highest in tumors localized to segment 8. The size and number of HCC tumors were not associated with an increased risk of microvascular invasion. PMID: 31186641 [PubMed]
Source: Journal of Cancer Epidemiology - Category: Epidemiology Tags: J Cancer Epidemiol Source Type: research
Patients with hepatocellular carcinoma waiting for liver transplantation are commonly treated with locoregional treatments, such as TACE and ablation, to prevent tumor progression and dropout and to improve lo...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Research article Source Type: research
Abstract Hepatocellular carcinoma represents an important cause of morbidity and mortality worldwide. It is the sixth most common cancer and the fourth leading cause of cancer death. Liver transplantation is a key tool for the treatment of this disease in human therefore hepatocellular carcinoma is increasing as primary indication for grafting. Although liver transplantation represents an outstanding therapy for hepatocellular carcinoma, due to organ shortage, the careful selection and management of patients who may have a major survival benefit after grafting remains a fundamental question. In fact, only some sta...
Source: World Journal of Gastroenterology : WJG - Category: Gastroenterology Authors: Tags: World J Gastroenterol Source Type: research
ConclusionsRadiomics signature extracted from CT images may be a potential imaging biomarker for liver cancer invasion and enable accurate prediction of HCC recurrence after liver transplantation.
Source: European Journal of Radiology - Category: Radiology Source Type: research
Genetic depletion of the tumor suppressor promyelocytic leukemia (PML) in combination with hepatitis C virus infection (HCVtg) was found to lead to increased hepatocyte proliferation in a rodent model, resulting in development of hepatocellular carcinoma (HCC) in PML ‐deficient livers. Findings correlate with profiles of samples from human livers of patients undergoing liver transplantation for HCC. The association between PML and HCV has been taken from a rodent model to human examples of HCC formation. AbstractPersistent infection with hepatitis C virus (HCV) is a known risk factor for the development of hepatocellular...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Cancers, Vol. 11, Pages 741: From a Philosophical Framework to a Valid Prognostic Staging System of the New “Comprehensive Assessment” for Transplantable Hepatocellular Carcinoma Cancers doi: 10.3390/cancers11060741 Authors: Sandro Bagnardi Cucchetti Lauterio De Carlis Benuzzi Danieli Botta Centonze Najjar De Carlis The comprehensive assessment of the transplantable tumor (TT) proposed and included in the last Italian consensus meeting still deserve validation. All consecutive patients with hepatocellular carcinoma (HCC) listed for liver transplant (LT) between January 200...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Publication date: Available online 10 May 2019Source: European Journal of RadiologyAuthor(s): Donghui Guo, Dongsheng Gu, Honghai Wang, Jingwei Wei, Zhenglu Wang, Xiaohan Hao, Qian Ji, Shunqi Cao, Zhuolun Song, Jiabing Jiang, Zhongyang Shen, Jie Tian, Hong ZhengAbstractObjectivesTo assess whether radiomics signature can identify aggressive behavior and predict recurrence of hepatocellular carcinoma (HCC) after liver transplantation.MethodsOur study consisted of 133 patients with clinically confirmed HCC after liver transplantation from October 2011 to December 2016. Radiomics features were extracted from hepatic artery phas...
Source: European Journal of Radiology - Category: Radiology Source Type: research
ConclusionWe identified a group of Metallothionein genes as biomarkers to predict recurrence. The metallothionein genes were all down ‐regulated in tumor samples, suggesting that low metallothionein expression may be a promoter of tumor growth. In addition, using de novo assembly identified some unique biomarkers, further confirmed the necessity of conducting a de novo assembly in human cancer study.
Source: Molecular Genetics & Genomic Medicine - Category: Genetics & Stem Cells Authors: Tags: ORIGINAL ARTICLE Source Type: research
Discussion MDSCs violently emerge in pathological conditions in an attempt to limit potentially harmful immune and inflammatory responses. Mechanisms supporting their expansion and survival are deeply investigated in cancer, in the perspective to reactivate specific antitumor responses and prevent their contribution to disease evolution. These findings will likely contribute to improve the targeting of MDSCs in anticancer immunotherapies, either alone or in combination with immune checkpoint inhibitors. New evidence indicates that the expansion of myeloid cell differentiation in pathology is subject to fine-tuning, as its...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Gastroenterology | Hepatocellular Carcinoma | Liver | Liver Cancer | Liver Transplant | Transplants | Urology & Nephrology